Bone marrow-derived mesenchymal stem cells co-expressing interleukin-18 and interferon-β exhibit potent antitumor effect against intracranial glioma in rats

Oncology Reports

Volumn 34, Issue 4, 2015, Pages 1915-1922

  Xu, Gang ^a   Guo, Yanwu ^b   Seng, Zhiyuan ^a   Cui, Gang ^a   Qu, Jianqiang ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Bone marrow derived mesenchymal stem cells; Glioma; Interferon ; Interleukin 18

Indexed keywords

BETA INTERFERON; INTERLEUKIN 18;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CANCER INHIBITION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; GENE THERAPY; GLIOMA; IN VITRO STUDY; IN VIVO STUDY; INTRACRANIAL TUMOR; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURVIVAL RATE; ANIMAL; BIOSYNTHESIS; BONE MARROW CELL; BRAIN NEOPLASMS; DISEASE MODEL; GENETICS; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY;

ANIMALS; BONE MARROW CELLS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GLIOMA; HUMANS; INTERFERON-BETA; INTERLEUKIN-18; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; RATS;

EID: 84939188692     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4174     Document Type: Article

References (45)

1. Mao XG, Zhang X and Zhen HN: Progress on potential strategies to target brain tumor stem cells. Cell Mol Neurobiol 29: 141-155, 2009.
2. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK and DePinho RA: Malignant glioma: Genetics and biology of a grave matter. Genes Dev 15: 1311-1333, 2001.
3. Sanai N and Berger MS: Glioma extent of resection and its impact on patient outcome. Neurosurgery 62: 753-764, discussion 264-266, 2008.
4. Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L, Scheding S and Bengzon J: Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther 17: 183-190, 2009.
5. Gunnarsson S, Bexell D, Svensson A, Siesjö P, Darabi A and Bengzon J: Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFNgamma-transduced tumor cell immunotherapy of experimental glioma. J Neuroimmunol 218: 140-144, 2010.
6. Matuskova M, Hlubinova K, Pastorakova A, Hunakova L, Altanerova V, Altaner C and Kucerova L: HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett 290: 58-67, 2010.
7. Suryadevara CM, Verla T, Sanchez-Perez L, Reap EA, Choi BD, Fecci PE and Sampson JH: Immunotherapy for malignant glioma. Surg Neurol Int 6 (Suppl 1): S68-S77, 2015.
8. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, et al: Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88-91, 1995.
9. Hwang KS, Cho WK, Yoo J, Seong YR, Kim BK, Kim S and Im DS: Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity. Cancer Gene Ther 11: 397-407, 2004.
10. Ossendorp F, Mengedé E, Camps M, Filius R and Melief CJ: Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187: 693-702, 1998.
11. Kohyama M, Saijyo K, Hayasida M, Yasugi T, Kurimoto M and Ohno T: Direct activation of human CD8+ cytotoxic T lymphocytes by interleukin-18. Jpn J Cancer Res 89: 1041-1046, 1998.
12. Xia D, Li F and Xiang J: Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity. Cancer Biother Radiopharm 19: 322-330, 2004.
13. Glick RP, Lichtor T, Mogharbel A, Taylor CA and Cohen EP: Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery 41: 898-906; discussion 906-907, 1997.
14. Sobol RE, Fakhrai H, Shawler D, Gjerset R, Dorigo O, Carson C, Khaleghi T, Koziol J, Shiftan TA and Royston I: Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 2: 164-167, 1995.
15. Hertzog PJ, Hwang SY and Kola I: Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol Reprod Dev 39: 226-232, 1994.
16. Nakahara N, Pollack IF, Storkus WJ, Wakabayashi T, Yoshida J and Okada H: Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Ther 10: 549-558, 2003.
17. W illiams RF, Myers AL, Sims TL, Ng CY, Nathwani AC and Davidoff AM: Targeting multiple angiogenic pathways for the treatment of neuroblastoma. J Pediatr Surg 45: 1103-1109, 2010.
18. Kageshita T, Mizuno M, Ono T, Matsumoto K, Saida T and Yoshida J: Growth inhibition of human malignant melanoma transfected with the human interferon-beta gene by means of cationic liposomes. Melanoma Res 11: 337-342, 2001.
19. Natsume A, Mizuno M, Ryuke Y and Yoshida J: Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther 6: 1626-1633, 1999.
20. Natsume A, Tsujimura K, Mizuno M, Takahashi T and Yoshida J: IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma. J Neurooncol 47: 117-124, 2000.
21. Xu G, Jiang XD, Xu Y, Zhang J, Huang FH, Chen ZZ, Zhou DX, Shang JH, Zou YX and Cai YQ: Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats. Cell Biol Int 33: 466-474, 2009.
22. Olson JJ, Friedman R, Orr K, Delaney T and Oldfield EH: Enhancement of the efficacy of x-irradiation by pentobarbital in a rodent brain-tumor model. J Neurosurg 72: 745-748, 1990.
23. Farrell CL, Stewart PA and Del Maestro RF: A new glioma model in rat: The C6 spheroid implantation technique permeability and vascular characterization. J Neurooncol 4: 403-415, 1987.
24. Chen W, Wang J, Shao C, Liu S, Yu Y, Wang Q and Cao X: Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur J Immunol 36: 1598-1607, 2006.
25. Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R, Grau S, Hiraoka N, Eckstein V, Ecker RC, et al: Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-. Clin Cancer Res 17: 4296-4308, 2011.
26. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA and Fearon DT: Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330: 827-830, 2010.
27. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, et al: Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65: 3307-3318, 2005.
28. Uchibori R, Okada T, Ito T, Urabe M, Mizukami H, Kume A and Ozawa K: Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med 11: 373-381, 2009.
29. Menon LG, Kelly K, Yang HW, Kim SK, Black PM and Carroll RS: Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 27: 2320-2330, 2009.
30. Tang XJ, Lu JT, Tu HJ, Huang KM, Fu R, Cao G, Huang M, Cheng LH, Dai LJ and Zhang L: TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells. Anticancer Res 34: 729-734, 2014.
31. Liu W, Han B, Sun B, Gao Y, Huang Y and Hu M: Overexpression of interleukin-18 induces growth inhibition, apoptosis and gene expression changes in a human tongue squamous cell carcinoma cell line. J Int Med Res 40: 537-544, 2012.
32. Liu W, Hu M, Wang Y, Sun B, Guo Y, Xu Z, Li J and Han B: Overexpression of interleukin-18 protein reduces viability and induces apoptosis of tongue squamous cell carcinoma cells by activation of glycogen synthase kinase-3 signaling. Oncol Rep 33: 1049-1056, 2015.
33. Zheng JN, Pei DS, Mao LJ, Liu XY, Sun FH, Zhang BF, Liu YQ, Liu JJ, Li W and Han D: Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis. Cancer Gene Ther 17: 28-36, 2010.
34. Takano S, Ishikawa E, Matsuda M, Yamamoto T and Matsumura A: Interferon- inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10. Int J Oncol 45: 1837-1846, 2014.
35. Yoshida J, Mizuno M and Yagi K: Cytotoxicity of human beta-interferon produced in human glioma cells transfected with its gene by means of liposomes. Biochem Int 28: 1055-1061, 1992.
36. Guo Y, Wang G, Gao WW, Cheng SW, Wang R, Ju SM, Cao HL and Tian HL: Induction of apoptosis in glioma cells and upregulation of Fas expression using the human interferon- gene. Asian Pac J Cancer Prev 13: 2837-2840, 2012.
37. Zhang Y, Wang C, Zhang Y and Sun M: C6 glioma cells retrovirally engineered to express IL-18 and Fas exert FasL-dependent cytotoxicity against glioma formation. Biochem Biophys Res Commun 325: 1240-1245, 2004.
38. Marshall DJ, Rudnick KA, McCarthy SG, Mateo LR, Harris MC, McCauley C and Snyder LA: Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine. Vaccine 24: 244-253, 2006.
39. Robertson MJ, Mier JW, Logan T, Atkins M, Koon H, Koch KM, Kathman S, Pandite LN, Oei C, Kirby LC, et al: Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res 12: 4265-4273, 2006.
40. Kikuchi T, Akasaki Y, Joki T, Abe T, Kurimoto M and Ohno T: Antitumor activity of interleukin-18 on mouse glioma cells. J Immunother 23: 184-189, 2000.
41. Yamanaka R and Xanthopoulos KG: Induction of antigenspecific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18. DNA Cell Biol 24: 317-324, 2005.
42. Yamanaka R, Honma J, Tsuchiya N, Yajima N, Kobayashi T and Tanaka R: Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. J Neurooncol 72: 107-113, 2005.
43. Yamanaka R, Tsuchiya N, Yajima N, Honma J, Hasegawa H, Tanaka R, Ramsey J, Blaese RM and Xanthopoulos KG: Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J Neurosurg 99: 746-753, 2003.
44. Meijer DH, Maguire CA, LeRoy SG and Sena-Esteves M: Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta. Cancer Gene Ther 16: 664-671, 2009.
45. Streck CJ, Dickson PV, Ng CY, Zhou J, Hall MM, Gray JT, Nathwani AC and Davidoff AM: Antitumor efficacy of AA V-mediated systemic delivery of interferon-beta. Cancer Gene Ther 13: 99-106, 2006.